Metabolic phenotypes of obesity: Frequency, correlates and change over time in a cohort of postmenopausal women

International Journal of Obesity

Volumn 41, Issue 1, 2017, Pages 170-177

  Kabat, G C ^a   Wu, W Y Y ^b,c   Bea, J W ^d   Chen, C ^e   Qi, L ^f   Stefanick, M L ^g   Chlebowski, R T ^h   Lane, D S ⁱ   Wactawski Wende, J ^j   Wassertheil Smoller, S ^a   Rohan, T E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d UNIVERSITY OF ARIZONA   (United States)

^e USA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g STANFORD UNIVERSITY   (United States)

^h HARBOR UCLA MEDICAL CENTER   (United States)

ⁱ STONY BROOK UNIVERSITY   (United States)

^j UNIVERSITY AT BUFFALO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; METABOLICALLY HEALTHY OBESITY; METABOLICALLY UNHEALTHY OBESITY; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; ABDOMINAL OBESITY; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLICATION; GLUCOSE BLOOD LEVEL; INFLAMMATION; INSULIN RESISTANCE; MARKOV CHAIN; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHENOTYPE; REPRODUCIBILITY; UNITED STATES;

BIOLOGICAL MARKER;

AGED; BIOMARKERS; BLOOD GLUCOSE; BODY FAT DISTRIBUTION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MARKOV CHAINS; METABOLIC SYNDROME; MIDDLE AGED; OBESITY, ABDOMINAL; PHENOTYPE; POSTMENOPAUSE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; UNITED STATES;

EID: 84995475920     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2016.179     Document Type: Article

References (48)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307: 491-497.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
3. Meigs JB. Epidemiology of the insulin resistance syndrome. Curr Diab Rep 2003; 3: 73-79.
4. Sathyaprakash R, Henry RR. Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep 2002; 2: 416-422.
5. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214.
6. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002; 3: 565-574.
7. Wildman RP. Healthy obesity. Curr Opin Nutr Metab Care 2009; 12: 438-443.
8. Reaven G. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diabetes Vasc Dis Res 2005; 2: 105-112.
9. Field AE, Camargo CA, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA 2013; 310: 2147-2148.
10. Karelis AD, St-Pierre DH, Conus F, Rabassa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004; 89: 2569-2575.
11. Pataky Z, Bobbioni-Harsch E, Golay A. Open questions about metabolically normal obesity. Int J Obesity 2010; 34: S18-S23.
12. Primeau V, Coderre L, Karelis AD, Brochu M, Lavoie ME, Messier V et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obesity 2011; 35: 971-981.
13. Den Engelsen C, Gorter KJ, Salomé PL, Rutten GE. Development of metabolic syndrome components in adults with a healthy obese phenotype: a 3-year follow-up. Obesity 2013; 21: 1025-1030.
14. Hwang YC, Hayashi T, Fujimoto WY, Kahn SE, Leonetti DL, McNeely MJ et al. Visceral fat accumulation predicts the conversion of metabolically healthy obese subjects to an unhealthy phenotype. Int J Obesity 2015; 39: 1365-1370.
15. Appleton SL, Seaborn CJ, Visvanathan R, Hill CL, Gill TK, Taylor AW et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype. Diabetes Care 2013; 36: 2388-2394.
16. Bell JA, Hamer M, Sabia S, Singh-Manoux A, Batty GD, Kivimaki M. The natural course of healthy obesity over 20 years (letter). J Am Coll Cardiol 2015; 65: 101-109.
17. Eshtiaghi R, Keihani S, Hosseinpnah F, Barzin M, Azizi F. Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: the Tehran Lipid and Glucose Study. Int J Obesity 2015; 39: 514-519.
18. Hamer M, Bell JA, Sabia S, Batty GD, Kivimäki M. Stability of metabolically healthy obesity over 8 years: the English Longitudinal Study of Aging. Eur J Endocrinol 2015; 173: 703-708.
19. Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obesity Rev 2014; 15: 504-515.
20. Lotta LA, Abbasi A, Sharp SJ, Sahlqvist A-S, Waterworth D, Brosnan JM et al. Definitions of metabolic health and risk of future type 2 diabetes in BMI categories: a systemic review and network meta-analysis. Diabetes Care 2015; 38: 2177-2187.
21. Fan J, Song Y, Chen Y, Hui R, Zhang W. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: a metaanalysis of prospective cohort studies. Int J Cardiol 2013; 168: 4761-4768.
22. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions: a systematic review and meta-analysis. Ann Int Med 2013; 159: 758-769.
23. Rey-Lopez JP, de Rezende LF, de Sá TH, Stamatakis E. Is the metabolically healthy obesity phenotype an irrelevant artifact for public health? Am J Epidemiol 2015; 182: 737-741.
24. Bradshaw PT, Stevens J. Invited commentary: limitations and usefulness of the metabolically healthy obesity phenotype. Am J Epidemiol 2015; 182: 742-744.
25. Ray-Lopez, de Rezende LF, de Sá TH, Stamatakis E, Ray-Lopez et al Respond to 'the metabolically healthy obesity phenotype.' Am J Epidemiol 2015;182:745-746.
26. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998; 47: 699-713.
27. Meigs JB, Wilson WF, Fox CS, Vasan RS, Nathan DM, Sullivan LM et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91: 2906-2912.
28. St Pierre AC, Cantin B, Mauriège P, Bergeron J, Dagenais GR, Després JP et al. Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. CMAJ 2005; 172: 1301-1305.
29. Song Y, Manson JE, Meigs JB, Ridker PM, Buring JE, Liu S. Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women. Am J Cardiol 2007; 100: 1654-1658.
30. Kuk JL, Arfern CI. Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diabetes Care 2009; 32: 2297-2299.
31. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 2003; 13: S5-S17.
32. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003; 13(9 Suppl): S107-S121.
33. Howard BV, Adams-Campbell L, Allen C, Black H, Passaro M, Rodabough RJ et al. Int J Obes Relat Metab Disord 2004; 28: 1039-1047
34. McTiernan A, Kooperberg C, White E, Wilcox S, Coates R, Adams-Campbell LL et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA 2003; 290: 1331-1336.
35. Bergmeyer HU, Bernt E, Schmidt F, Stork H. Determination of hexiokinase and glucose-6-phosphate dehydrogenase. In: Bergmeyer HU (eds). Methods of Enzymatic Analysis. 2nd edn. Academic Press: New York, NY, USA, 1974, pp 1196.
36. Peterson JI, Young DS. Evaluation of the hexokinase-glucose-6-phosphate dehydrogenase method of determination of glucose in urine. Anal Biochem 1968; 23: 301-316.
37. Tietz NW. Fundamentals of Clinical Chemistry, 3rd edn. WB Saunders Co: Philadelphia, PA, USA, 1987; p 544.
38. Steiner P, Freidel J, Bremmer W, Stein E. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the lipid clinics' methodology. J Clin Chem Clin Biochem 1981; 19: 850-851.
39. National Heart, Lung, and Blood Institute. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), final report. NIH Publication No. 02-5215, September 2002.
40. Grundy SM, Cleeman JI, Daniels ST, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
41. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
42. Kuo HS, Chang HJ, Chou P, Teng L, Chen THH A. Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). Int J Epidemiol 1999; 28: 233-240.
43. Hinnouho G-M, Czernichow S, Dugravot, Nabi H, Brunner EJ, Kivimaki M et al. Metabolically healthy obesity and risk of mortality. Diabetes Care 2013; 36: 2294-2300.
44. Thomsen M, Nordesgaard BC. Myocardial infarction and ischemic heart disease in overweight and obesity with and without the metabolic syndrome. JAMA 2013; 174: 15-22.
45. Kip KE, Marroquin OC, Kelley DE, Johnson D, Kelsey SF, Shaw LJ et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 2004; 109: 706-713.
46. Berrahmoune H, Herbeth B, Samara A, Marteau J-B, Visvikis-Siest S. Five-year alterations in BMI are associated with clustering of changes in cardiovascular risk factors in a gender-dependent way: the Stanislas study. Int J Obesity 2008; 32: 1279-1288.
47. Rutter MK, Sullivan LM, Fox CS, Wilson PWF, Nathan DM, Vasan RS et al. Baseline levels, and changes over time in body mass index and fasting insulin, and their relationship to change in metabolic trait clustering. Metab Syndr Relat Disord 2014; 12: 372-380.
48. Bradshaw PT, Monda KL, Stevens J. Metabolic syndrome in healthy obese, overweight, and normal weight individuals: the Atherosclerosis Risk in Communities Study. Obesity 2013; 21: 203-209.